The journal Nature Communications published the study, which shows that in renal cell carcinoma androgen signaling can either stimulate or suppress tumor cells' movement and invasion to different locations in the body.
In earlier research, the lab also shed light on the duality of AR's role in different cancers. For example, AR signaling can enhance bladder cancer cell invasion but suppress prostate cancer cell invasion.
"In kidney cancer, many studies have provided conflicting information," senior author said. "In some cases AR expression has been associated with less malignancy. We were able to begin to sort out AR's function in this one disease, showing that AR-positive kidney tumors are more likely to spread to the lungs and AR-negative tumors are more likely to spread to the lymph nodes."
The lab began its investigation with an epidemiology survey of nearly 4,000 cases of kidney cancer in China. Researchers found that, generally, males were almost three times as likely to get kidney cancer as females. And among those whose cancer spread to the lungs within 12 months, the male-to-female ratio jumped to nearly five to one. In contrast, the gender differences were much less significant among the patients whose cancer spread to lymph nodes versus to the pulmonary system, presumably because the cancer cells contained fewer androgen receptors.
The next phase of their research included studying human cells and tissue to understand the mechanisms by which signaling among AR proteins interacted with other known cancer-associated genes to enhance or reduce metastasis.
Mechanistically, AR enhances miR-185-5p expression via binding to the androgen response elements located on the promoter of miR-185-5p, which suppresses VEGF-C expression via binding to its 3′ UTR. In contrast, AR-enhanced miR-185-5p also promotes HIF2α/VEGF-A expression via binding to the promoter region of HIF2α. These results provide a unique mechanism by which AR can either increase or decrease renal cancer metastasis in different sites.
Renal cell carcinoma or kidney cancer is often treated with surgery and radiation in less advanced cases, and also with chemotherapy, immunotherapy, and some newer, targeted drugs that block the growth-stimulating proteins in the cancer cells. However, once it has spread it is difficult to treat. The cancer tends to resist chemotherapy and radiation, and targeted medications only extend survivorship an average of six to 15 months.
Mechanism of androgen receptor mediated kidney cancer metastases
- 1,208 views